This website uses cookies

This website uses cookies to improve user experience. By using our website you consent to all cookies in accordance with our Cookie Policy.

Some cookies on this site are essential, and the site won't work as expected without them. These cookies are set when you submit a form, login or interact with the site by doing something that goes beyond clicking on simple links.

We also use some non-essential cookies to anonymously track visitors or enhance your experience of the site. If you're not happy with this, we won't set these cookies but some nice features of the site may be unavailable.


n.c.a. 177Lu-DOTA-Zoledronate / 68Ga-DOTA-Zoledronate

DOTA-Zoledronate is a next generation agent for bone Targeted Radionuclide Therapy and diagnostics in patients suffering from bone metastases. DOTA-Zoledronate specifically targets cancerous bone lesions and, when radiolabeled with therapeutic or diagnostic radioisotopes, has shown high potential for PET-Imaging and radionuclide therapy.

This novel bisphosphonate derivative is attractive for tagging of beta-emitting n.c.a. Lutetium-177 (EndolucinBeta®) as well as the generator derived PET-radionuclide Gallium-68. Due to its versatile properties for radiolabeling, DOTA-Zoledronate is also a promising precursor for the development of other future-oriented radionuclide therapeutic concepts in the field of Precision Oncology, such as targeted alpha particle therapy.